Kite Wins EMA Recommendation To Market Tecartus For Leukemia Patients

The European Medicines Agency has recommended new uses for six approved products, including the CAR T-cell therapy Tecartus. 

CAR T Therapy written in white chalk on a black chalkboard isolated on white
Tecartus is administered as a one-time infusion • Source: Shutterstock

Tecartus (brexucabtagene autoleucel), Kite Pharma’s CAR T-cell therapy for mantle cell lymphoma, is on track to becoming approved in the EU for an expanded indication – acute lymphoblastic leukemia (ALL).

The European Medicines Agency’s human medicines committee, the CHMP, recommended in favor of authorizing the new indication last week. If...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>